Proteome Sciences plc
("Proteome Sciences" or the "Company")
Annual General Meeting Statement
At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, will make the following statement:
Since the start of 2024, we have seen significant customer engagement and interest in proteomics services reflected by the considerable increase in customer contact and quotations provided, including the substantial contract win from a US biopharmaceutical company announced on 26 April 2024.
The Company is confident and well positioned to see the business return to growth in 2024, following the launch of single cell proteomics ("SCP"), the introduction of new next generation tags in the isobaric and isotopic field, and the opening of the new facility in the USA during 2023 to provide services locally.
For further information:
|
Proteome Sciences plc | ||
| Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer | Tel: +44 (0)20 7043 2116 |
|
| Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer |
|
|
|
|
|
|
| Allenby Capital Limited (Nominated Adviser & Broker) |
| |
| John Depasquale / Lauren Wright (Corporate Finance) Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)
| Tel: +44 (0) 20 3328 5656 |
|
|
| ||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
